{"entity":{"id":"xport-ec-042","kind":"trial","name":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083","aka":[],"tldr":"XPORT-EC-042 tested maintenance selinexor against placebo in TP53-normal advanced endometrial cancer after response to platinum chemotherapy, chasing a subgroup finding from the earlier SIENDO trial. It missed its primary endpoint in July 2026: a trend favoured selinexor but did not reach statistical significance, a lesson in the limits of post-hoc biomarker subgroups.","summary":"The primary PFS endpoint was not met (topline 30 July 2026). A trend favoured selinexor in the modified intent-to-treat population (median PFS 12.75 vs 7.43 months), consistent with the SIENDO exploratory subgroup that motivated the trial, but not statistically significant. Karyopharm cut its endometrial investment. A lesson in the limits of post-hoc biomarker subgroups.","status":"negative","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT05611931","url":"https://clinicaltrials.gov/study/NCT05611931"},{"label":"Karyopharm topline","url":"https://investors.karyopharm.com/2026-07-30-Karyopharm-Announces-Topline-Results-from-Phase-3-XPORT-EC-042-Trial-in-Endometrial-Cancer"}],"tags":["failure","lesson:subgroup"],"related":[],"cancers":["endometrial","advanced-recurrent-endometrial-cancer","endometrial-nsmp"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["tp53"],"drugs":["selinexor"],"companies":["karyopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05611931","phase":"3","setting":"TP53-wild-type advanced or recurrent endometrial cancer after response to platinum: maintenance selinexor vs placebo","sponsor":"Karyopharm","result":"Primary PFS endpoint not met; mPFS 12.75 vs 7.43 months (mITT) not significant.","started":"2023-04-18","startedType":"actual","yearReported":2026,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (mITT)","primary":true,"unit":"months","arms":[{"name":"Selinexor","value":12.75,"note":"Not statistically significant"},{"name":"Placebo","value":7.43}],"p":"not significant","source":"https://investors.karyopharm.com/2026-07-30-Karyopharm-Announces-Topline-Results-from-Phase-3-XPORT-EC-042-Trial-in-Endometrial-Cancer"}]},"route":"/trials/xport-ec-042/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"drug":[{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/"}],"company":[{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/"}]}}